Sarepta Therapeutics (SRPT) : The total negative money flow of $2.82 million on Wednesday indicates selling on strength. The inflow of money on upticks was $132.65 million, compared to $135.47 million outflow on downticks, which confirms distribution in the stock. The up to down ratio was 0.98. The negative money flow of $1.35 million in block trades reveals that the informed traders sold the stock on every bit of price strength. The traded value of the stock on uptick was $3.4 million in a block trade.The transaction value of block trade on downtick was $2.05 million. The uptick to downtick ratio was 1.66. The price action in the Sarepta Therapeutics (SRPT) stock suggests that both the bulls and the bears were in equilibrium. The stock traded at $62.4 with a gain of $3.3 , a change of 5.58% over the previous days close. The stock registered 7.9% for the week.
Shares of Sarepta Therapeutics, Inc. rose by 10.71% in the last five trading days and 127.15% for the last 4 weeks. Sarepta Therapeutics, Inc. is up 233.55% in the last 3-month period. Year-to-Date the stock performance stands at 61.33%.
Sarepta Therapeutics (SRPT) has an average broker rating of 1.62, which is interpreted as a Buy, as rated by 13 equity analysts. Nonetheless, 8 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. 2 other analysts advise a Buy. Nevertheless, the majority of 3 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.
Sarepta Therapeutics (NASDAQ:SRPT): The stock opened at $61.8 and touched an intraday high of $63.73 on Wednesday. During the day, the stock corrected to an intraday low of $60.57, however, the bulls stepped in and pushed the price higher to close in the green at $62.24 with a gain of 5.31% for the day. The total traded volume for the day was 8,350,495. The stock had closed at $59.1 in the previous trading session.
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of unique ribonucleic acid (RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company is primarily focused on advancing the development of its potentially disease-modifying Duchenne Muscular Dystrophy (DMD) drug candidates, including its lead DMD product candidate, eteplirsen, which is an antisense PMO therapeutic in Phase III clinical development for the treatment of individuals with DMD who have an error in the gene coding for dystrophin that is amenable to skipping exon 51. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases.